"Pharmaceutical Speed ​​Reading Society" China's new crown therapeutic antibody new drug was approved in Europe and the United States for emergency use...

[March 15th, 2021 / List of medical information] China's new drug developed for the new crown therapeutic antibody was approved for emergency use in Europe and the United States; CSPC obtained the exclusive right of CM310 in China.

Part1 Policy Brief

Part1 policy briefing Part1 policy briefing

Beijing Chaoyang Court: The illegal practice of medical and aesthetic institutions has been repeatedly banned and the punishment is too light

Beijing Chaoyang Court: The illegal practice of medical and aesthetic institutions has been repeatedly banned and the punishment is too light

Today, Beijing Chaoyang Court notified the White Paper on Trial of Medical Beauty Disputes and Typical Cases.

Is vaccination of new crown vaccine causing blood bank strain? National Health Commission: Stable blood supply across the country

Is vaccination of new crown vaccine causing blood bank strain? National Health Commission: Stable blood supply across the country

In response to the claim that residents' vaccination of the new crown vaccine has caused blood banks in some areas to be strained, Chang Jile, director of the National Health Commission’s Disease Control Bureau, said on the 15th that in accordance with the current blood donor health check requirements, the blood donation time will be suspended from 24 hours according to the different types of vaccinations.

Part2 Observation

Part2 Sankei Observation Part2 Sankei Observation

Livzon Biotech's senior management information changes

Livzon Biotech's senior management information changes

On March 15th, Livzon Biological announced that it would appoint Professor Mao Li as the general manager and chief medical officer; and Dr.

Deck Pharma appoints Minyoung Kim as General Manager of Deck Korea

Deck Pharma appoints Minyoung Kim as General Manager of Deck Korea

On March 15, Deck Pharmaceuticals announced that the company officially appointed Minyoung Kim as the general manager of Deck Korea.

CSPC obtains exclusive rights to anti-IL-4Rα monoclonal antibody CM310 in China

CSPC obtains exclusive rights to anti-IL-4Rα monoclonal antibody CM310 in China

On the 10th, CSPC issued an announcement stating that its wholly-owned subsidiary Jinmante Biological had entered into an agreement with Connoa Biological.

Roche Pharmaceuticals acquires US molecular diagnostics company for US$1.

Roche Pharmaceuticals acquires US molecular diagnostics company for US$1.

Hanyu Medical completed nearly 500 million yuan in D+ round of financing

Hanyu Medical completed nearly 500 million yuan in D+ round of financing

Artery Network was informed for the first time that on March 15, 2021, Hanyu Medical officially announced the completion of a D+ round of financing with a total amount of nearly 500 million yuan; this round of financing introduced lead investors Fang Yunfeng Fund, as well as Jiangsu Ruihua, Octagon Capital, and E Fund Capital , Leading Capital and other investors, the original shareholder Honghui Capital continued to invest.

Part3 Medicine News

Part3 Medicine News

The first phase II "sound and light" therapy for Alzheimer's disease has positive results

The first phase II "sound and light" therapy for Alzheimer's disease has positive results

On March 9, Cognito Therapeutics, a US clinical stage company, announced at the 15th International Conference on Alzheimer’s and Parkinson’s Disease that it has developed an innovative digital therapy for the treatment of AD through sound and light stimulation in a phase II clinical trial.

Baiji China starts clinical trial HPK1 an inhibitor of a test

BeiGene initiates a phase 1 clinical trial of HPK1 inhibitor

Recently, BeiGene announced that a phase 1 clinical trial of its in-development hematopoietic stem cell kinase 1 (HPK1) inhibitor BGB-15025 has completed its first patient administration.

Jingfeng Pharmaceutical Lincomycin Hydrochloride Injection was approved by the US ANDA

Jingfeng Pharmaceutical Lincomycin Hydrochloride Injection was approved by the US ANDA

On March 15th, Jingfeng Pharmaceutical issued an announcement stating that its holding subsidiary had recently received a notice from the FDA that the abbreviated new drug application for Lincomycin Hydrochloride Injection has been approved.

Yifan Pharmaceutical's Recombinant Human Growth Hormone for Injection Approved for Clinical Trial

Yifan Pharmaceutical's Recombinant Human Growth Hormone for Injection Approved for Clinical Trial

On the 12th, Yifan Pharmaceutical issued an announcement stating that its subsidiary received approval from NMPA regarding the approval of recombinant human growth hormone-Fc fusion protein for injection in the Drug Clinical Trial Approval Notice, and agreed to develop growth hormone deficiency in children and adult growth.

Enhua Pharmaceutical's Class 1 chemical drug NH102 hydrochloride tablets was approved for clinical use

Enhua Pharmaceutical's Class 1 chemical drug NH102 hydrochloride tablets was approved for clinical use

On March 15th, Enhua Pharmaceuticals issued an announcement stating that it had recently received the "Drug Clinical Trial Approval Notice" for 3 specifications of NH102 Hydrochloride Tablets, a category 1 chemical drug approved and issued by NMPA, and will start clinical trials in the near future .

Conba Pharmaceutical's Lacosamide Oral Solution Marketing Application Approved

Conba Pharmaceutical's Lacosamide Oral Solution Marketing Application Approved

On the 12th, CDE official website data showed that Shanghai Aokeda Biomedical Technology|Zhejiang Kangenbei Pharmaceutical Co.

CStone's RET inhibitor "Platinib Capsules" will be approved soon

CStone's RET inhibitor "Platinib Capsules" will be approved soon

On March 12, the listing application of CStone's RET inhibitor "Platinib Capsules" was changed to "Under Approval" in NMPA, and it is expected to be officially approved in the near future.

Jianfan Bio: Obtained the medical device registration certificate for disposable hemodialysis tubing

Jianfan Bio: Obtained the medical device registration certificate for disposable hemodialysis tubing

Jianfan Biological announced on the 15th that the company recently received the "Medical Device Registration Certificate" issued by the National Medical Products Administration.
The product name is a single-use hemodialysis tube.
The registration certificate is valid from March 10, 2021.
On March 9, 2026, the scope of application: it is used for the function of blood access during hemodialysis treatment.
(Jianfan Biological Announcement)

China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States

China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States

Today, it is learned from the Institute of Microbiology of the Chinese Academy of Sciences that the European Medicines Agency’s Committee on Medicinal Products for Human Use has recently allowed EU member states to use the combination therapy of monoclonal antibodies LY-CoV555 and LY-CoV016 ("antibody cocktail") in public health emergencies.
Treatment) Coping with patients with new coronary pneumonia infection.
(Associated Finance Press)

BMS and AVEO reach cooperation on Opdivo and Fotivda in the treatment of kidney cancer

BMS and AVEO reach cooperation on Opdivo and Fotivda in the treatment of kidney cancer

A few days ago, AVEO Oncology announced that it has signed a clinical trial cooperation and supply agreement with Bristol-Myers Squibb to study the efficacy of Fotivda combined with Bristol-Myers Squibb’s PD-1 tumor drug Opdivo in the treatment of patients with advanced refractory or relapsed renal cell carcinoma who have received immunotherapy .
(Sina Pharmaceutical News)